Veritas In Silico Inc. (JP:130A) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Veritas In Silico Inc. is expanding its global reach by securing a patent in Europe for its innovative method in RNA-targeted drug discovery. This strategic move is expected to enhance their proprietary drug discovery platform, ibVIS®, despite the patent having a minimal immediate impact on business performance. The company anticipates significant future progress from this development.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.